Von Willebrand disease (VWD) is the most common inherited bleeding disorder. It can be associated with a life-threatening risk of excessive bleeding in surgical procedures, and may require prophylactic treatment with a combined factor VIIII (FVIII)/von Willebrand factor (VWF) concentrate. Management of these patients may be challenging when trying to achieve the balance between avoiding the risk of haemorrhage and causing a risk of thrombosis with the treatment. We present a complex case of severe thrombocytopenia in a post-surgical setting, in which the timeline suggests a direct relationship between the worsening of platelet count and wilate administrations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11846128 | PMC |
| http://dx.doi.org/10.7759/cureus.77868 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances in sulodexide-based long-term anticoagulation for a myasthenia gravis patient with giant thymoma.
Front Pharmacol
February 2025
Department of Intensive Care Unit, Renmin Hospital of Wuhan University, Wuhan, China.
This case report describes a geriatric male patient with myasthenia gravis (MG) secondary to giant thymoma, presenting with progressive muscle weakness and ptosis. The diagnosis of MG was confirmed through pathology, imaging, and laboratory evaluations. Considering the significant surgical risks associated with the giant thymoma, adjuvant chemotherapy was initiated.
View Article and Find Full Text PDFA Novel Variant of the FERMT3 Gene Associated With Leukocyte Adhesion Deficiency Type III (LAD-III) in a Saudi Family: A Case Series.
Cureus
February 2025
Department of Pediatrics, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, SAU.
Leukocyte adhesion deficiency type III (LAD-III) is a rare autosomal recessive disorder characterized by immune dysfunction and bleeding tendencies. The condition arises from mutations in the FERMT3 gene, which disrupts integrin activation on leukocytes and platelets. This case study focuses on a family with consanguineous parents and multiple affected individuals spanning two generations, all diagnosed with LAD-III due to a novel homozygous mutation in the FERMT3 gene (c.
View Article and Find Full Text PDFBackground: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne infectious disease discovered in the 21st century. Human-to-human transmission of the disease has been documented, but the mechanisms of transmission require further investigation.
Methods: Epidemiological investigations and genetic analyses of the patients were conducted, and a retrospective cohort study was performed to analyze potential risk factors for person-to-person transmission.
Olezarsen: First Approval.
Drugs
March 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Olezarsen (TRYNGOLZA™) is a first-in-class, GalNAc-conjugated antisense oligonucleotide being developed by Ionis Pharmaceuticals for the treatment of familial chylomicronaemia syndrome (FCS) and severe hypertriglyceridaemia. It binds to apoC-III mRNA, promoting its degradation and lowering serum apoC-III protein levels. This action lowers triglyceride levels by enhancing the clearance of plasma triglyceride-rich lipoproteins such as chylomicrons and very-low-density lipoproteins.
View Article and Find Full Text PDFKaempferide enhances type I interferon signaling as a novel broad-spectrum antiviral agent.
Antiviral Res
March 2025
Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071/430207, China; State Key Laboratory of Virology and Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071/430207, China; Hubei Jiangxia Laboratory, Wuhan 430207, China. Electronic address:
Broad-spectrum antivirals (BSAs) possess unique advantages of being effective against a wide range of both existing and unpredictable emerging viral infections. The host type I interferon (IFN) response serves as a universal defense against diverse viral infections nonspecifically, providing attractive targets to develop novel BSAs. In this study, we identified the flavonoid kaempferide as an enhancer of the type I IFN activated Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway, promoting the expression of IFN stimulated genes (ISGs) and the establishment of cellular antiviral status.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!